TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03432247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy
Description: Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal support
Description: Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
Study: NCT02723201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 IRT
Description: TAK-020 immediate release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 CCT
Description: TAK-020 co-crystal tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 Solid Formulation
Description: TAK-020 solid formulation
Study: NCT00425672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONTAK
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01012674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF MRA
Description: Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
Study: NCT00425672

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study: NCT01836341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT01112280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted chromoendoscopy
Description: A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
Study: NCT02678286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study: NCT03725605

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LTX-315 and TILs
Description: Intratumoural injection of LTX-315 and infusion of TILs
Study: NCT00840138

Intervention type: PROCEDURE
Intervention: Surgical reconstruction
Description: Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube

Intervention type: PROCEDURE
Intervention: Surgical reconstruction
Description: Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube
Study: NCT02819934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD101
Description: after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
Study: NCT02731365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
Study: NCT02438722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib Dimaleate
Description: Given PO
Study: NCT02723201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020 Solid Formulation
Description: TAK-020 solid formulation
Study: NCT03588741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa
Description: Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month.
Study: NCT01650870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline Lactulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalline Lactulose
Study: NCT00984620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV)
Study: NCT00662532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl
Description: 1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
Study: NCT02438722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03236753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread-embedding Acupuncture (TEA)
Description: The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Thread-embedding Acupuncture (STEA)
Description: All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
Study: NCT03124420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lansoprazole
Description: Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Amoxicillin
Description: Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Clarithromycin
Description: Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
Study: NCT00354198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
Study: NCT05713994

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: PROCEDURE
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: DRUG
Intervention: Bevacizumab plus Atezolizumab
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)

Intervention type: DRUG
Intervention: Bevacizumab Biosimilar IBI305 plus sintilimab
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)

Intervention type: DRUG
Intervention: Lenvatinib
Description: 8mg; p.o.; q.d.
Study: NCT03728283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement in combination with connective tissue grafting
Description: A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
Study: NCT05713994

Intervention type: DRUG
Intervention: Sorafenib
Description: 400mg; p.o. bid

Intervention type: DRUG
Intervention: Donafenib
Description: 200mg; p.o. bid
Study: NCT03728283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implants were placed following teh manufacturer's instructions
Study: NCT01290796

Intervention type: DEVICE
Group type: OTHER
Intervention: Ajust Adjustable Single-Incision Sling
Description: The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
Study: NCT03087617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imbio Smoking Cessation Report
Description: Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imbio Smoking Cessation Report
Description: Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 45 minute counseling session with a tobacco treatment specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: 45 minute counseling session with a tobacco treatment specialist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.
Study: NCT05713994

Intervention type: DRUG
Intervention: Regorafenib
Description: 160 mg; p.o.; q.d.

Intervention type: DRUG
Intervention: apatinib plus camrelizumab
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Study: NCT01597063

Intervention type: DEVICE
Intervention: SEQureDx Trisomy Test
Description: Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
Study: NCT01946178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirabilis High-Intensity Focused Ultrasound Treatment System
Description: The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
Study: NCT02493348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic Sensory Stimulation
Description: Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Sensory Stimulation
Description: Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
Study: NCT00006227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01100489

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
Study: NCT01445535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
Study: NCT02718378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05713994

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Study: NCT02264054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]talsaclidine, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C]talsaclidine, iv
Study: NCT02421887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant Supplement
Description: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00381407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training
Description: Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
Study: NCT03087617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care for Lung Cancer Screening patients.
Study: NCT01896206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CNAP monitor
Description: Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
Study: NCT02543749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Autologous DC pulsed with leukemia-associated peptides+adjuvant